Market Overview

Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Clovis Oncology Inc (NASDAQ: CLVS) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK)'s proposed acquisition of TESARO Inc (NASDAQ: TSRO), according to Gabelli Research.

The Analyst

Analyst Jing He named Clovis as his top pick in 2019. The analyst reiterated a Buy rating on Clovis shares.

The Thesis

The Tesaro deal and Merck & Co., Inc. (NYSE: MRK)'s $5-billion purchase of half of the commercial rights of AstraZeneca plc (NYSE: AZN)'s Lynparza in 2017 leave Clovis as the sole standalone PARP oncology company, giving it a scarcity value, analyst He said in a Tuesday note. (See his track record here.)

Clovis is the most likely takeout target in 2019, with Bristol-Myers Squibb Co (NYSE: BMY), Novartis AG (NYSE: NVS)' Sanofi and Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) among the potential suitors, the analyst said. 

Clovis' Rubraca — a PARP inhibitor — is being evaluated in combination with Bristol-Myers' Opdivo as a first-line maintenance therapy for ovarian cancer in the ATHENA trial, He said. Data from the trial is expected in early 2021.

Although Clovis is behind the AstraZeneca-Merck combine and Tesaro-GSK in development, Clovis is in a better long-term position due to data generated by the Rubraca-Opdivo combination, He said. 

Clovis is evaluating Rubraca as monotherapy to treat prostate cancer in TRITON2 and TRITON3 trials, thr 

The company looks forward to filing application to the FDA by year-end 2019, the analyst said. 

Gabelli views data updates from TRITON2/3 trials at the ASCO meeting in June as the next catalysts for Clovis shares. 

The Price Action

Clovis shares were higher by more than 1 percent at $21.96 at the time of publication Tuesday.

Related Links:

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Latest Ratings for CLVS

Nov 2019DowngradesOutperformIn-Line
Oct 2019MaintainsSell
Sep 2019DowngradesOutperformMarket Perform

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Gabelli Jing He oncologyAnalyst Color Biotech Reiteration Analyst Ratings General Best of Benzinga


Related Articles (AZN + BMY)

View Comments and Join the Discussion!

Latest Ratings

ROSTMKM PartnersMaintains121.0
BJDeutsche BankMaintains27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

What China's iPhone Ruling Means For Qualcomm And Apple

Roku Under Selling Pressure Amid Report TCL Is Shifting Its Business